Praill Anthony Scott 4
4 · Kintara Therapeutics, Inc. · Filed Apr 29, 2021
Insider Transaction Report
Form 4
Praill Scott
CFO
Transactions
- Conversion
Common Stock
2021-04-29+938→ 8,486 total - Conversion
Series B Convertible Preferred Stock
2021-04-29−3,750→ 0 totalFrom: 2016-04-29→ Common Stock (938 underlying) - Other
Common Stock
2021-04-29+8→ 7,548 total
Footnotes (3)
- [F1]The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock.
- [F2]Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.
- [F3]Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.